Record 2003 revenues

Guava Technologies, a biomedical products company focused on developing and commercialising cell-based analysis systems for life science R and D and clinical diagnostics, has announced that it doubled revenues from sales of its innovative products during 2003 for the second consecutive year.

Triple-digit revenue growth was driven by strong sales of the Guava PCA, Guava PCA-96, and the Guava PCA-96 AFP systems, as well as key reagent and software products.

"New products, fuelled by strong demand from cell biology research customers at top pharmaceutical and biotechnology companies, as well as many academic and government laboratories, drove sales growth," said Rajen Dalal, president and chief executive officer of Guava Technologies. "Our expanded sales and marketing team has been very effective at demonstrating to more customers that Guava's turnkey micro-volume approach to cell analysis and counting makes sophisticated cellular assays more affordable and accessible, reducing research time and the cost of discovering and developing new therapies and vaccines".

Guava Technologies has today installed hundreds of systems at leading research organisations worldwide.

All of the top 20 pharmaceutical and the top ten biotechnology companies, as well as the National Institutes of Health and many leading universities and government labs have purchased one or more Guava instruments for their cell analysis research.

During 2003, Guava launched the Guava PCA-96 system, a green-laser based system that can count, screen, and profile cells in the highly productive 96-well plate format.

The Guava PCA-96 began shipping in May 2003.

Guava also launched its new Guava PCA-96 AFP sstem in October 2003, the only solid state blue-laser, micro-volume cell analysis system capable of screening single cells at the research bench top for GFP (green fluorescent protein) expression in an automated format.